Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622505 · ClinicalTrials.gov registry record · Phase 4
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
A Phase 4 study of Multiple Myeloma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT00622505: Completed Phase 4 study of Multiple Myeloma, sponsored by Novartis Pharmaceuticals.
NCT00622505 is a Phase 4 study of Multiple Myeloma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 121 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00622505, a Phase 4 study of Multiple Myeloma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
Primary Outcome
SRE was defined as pathological bone fracture, initiation of radiotherapy or surgery on bone, spinal cord compression, or hypercalcemia of malignancy (HCM). SRE was assessed by centrally read radiographic bone surveys.
Conditions Studied
Interventions
- DRUG zoledronic acid
Study Locations (20)
California
- Wilshire Oncology Medical Group - La Verne
- Cedars Sinai Medical Center Outpatient Cancer Ctr. (4) - Los Angeles
- Palo Alto Medical Foundation Hematology/Oncology - Mountain View
- Oncology Care Medical Associates - San Gabriel
- Santa Clara Valley Health & Hospital System - San Jose
Florida
- Palm Beach Institute of Hematology Oncology - Boynton Beach
- Innovative Medical Research of South Florida Innovative Med Research - Miami Shores
- Cancer Centers of Florida PA Cancer Centers of Central FL - Ocoee
- Integrated Community Oncology Network Florida Oncology Associates - Orange Park
- Cleveland Clinic Florida - Weston
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
- Center for Cancer & Blood Disorders - Bethesda
- Oncology - Hematology Associates, PA Oncology Hematology Assoc - Clinton
Massachusetts
- Dana Farber Cancer Institute Clinical Research Coordinator - Boston
- Boston VA Healthcare Boston VA - Boston
Arizona
- TriValley Cancer Research and Treatment Center - Casa Grande
Colorado
- University of Colorado U of Colorado Cancer Center - Aurora
Connecticut
- Hematology Oncology PC - Stamford
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2007-11-07 |
| Est. Completion | 2012-04-03 |
| Phase | Phase 4 |
What the finished NCT00622505 record still lists
NCT00622505 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00622505 names 20 study sites across 9 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00622505 about?
NCT00622505 is a clinical study titled "Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants". This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
What is the current status of trial NCT00622505?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2007-11-07. Estimated completion is 2012-04-03.
What conditions does trial NCT00622505 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00622505?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00622505?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00622505 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00622505's enrollment target sits among peer trials
121 151st of 438 higher than 288 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI